Tower Research Capital LLC (Trc) Recursion Pharmaceuticals, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.39 Billion
- Q3 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 161,671 shares of RXRX stock, worth $669,317. This represents 0.02% of its overall portfolio holdings.
Number of Shares
161,671
Previous 77,170
109.5%
Holding current value
$669,317
Previous $390,000
102.05%
% of portfolio
0.02%
Previous 0.01%
Shares
18 transactions
Others Institutions Holding RXRX
# of Institutions
362Shares Held
301MCall Options Held
7.71MPut Options Held
4.85M-
Vanguard Group Inc Valley Forge, PA39.8MShares$165 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl33.5MShares$139 Million1.15% of portfolio
-
Baillie Gifford & CO24MShares$99.3 Million0.09% of portfolio
-
State Street Corp Boston, MA18.3MShares$75.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$71.7 Million0.0% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $747M
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...